Oramed Pharmaceuticals was Chosen to Present Results of a GLP-1 Analog Oral Administration Study.

Summary: Oramed Pharmaceuticals was Chosen to Present Results of a GLP-1 Analog

Oramed Pharmaceuticals was Chosen to Present Results of a GLP-1 Analog Oral Administration Study at the Diabetes Technology Society's Ninth Annual Meeting (November 5-7, 2009; San Francisco, CA)

JERUSALEM, October 20/PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc.(OTCBB: ORMP.OB; http://www.oramed.com), a developer of oral drug delivery systems, announced today that its poster entitled "A novel GLP-1 analog delivered orally reduces postprandial glucose excursions in a porcine model," has been accepted for presentation at the Diabetes Technology Society's Ninth Annual Meeting in San Francisco, California between November 5-7, 2009.

"The selection of Oramed as one of the companies to present at theDiabetes Technology Conference is a wonderful opportunity for us todemonstrate our technology to the world's leading diabetes scientists," saidNadav Kidron, Oramed CEO.

Oramed's abstract will be presented on Thursday November 5, 2009, at 5:30PM. The poster will be available for viewing throughout the conference.

For more information about the Diabetes Technology Society's Ninth AnnualMeeting, please visit http://www.diabetestechnology.org/

For more information about Oramed Pharmaceuticals, please visithttp://www.oramed.com

2009 Al Bawaba (www.albawaba.com)

2009 Al Bawaba (Albawaba.com)

Provided by Syndigate.info an Albawaba.com company